Table of Contents
ISRN Hematology
Volume 2011 (2011), Article ID 623924, 14 pages
http://dx.doi.org/10.5402/2011/623924
Research Article

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

1Department of Internal Medicine, Mercer University, Central Georgia Cancer Care, 1062 Forsyth Street, Suite 1B Macon, Georgia, GA 31201, USA
2Department of Hematology Oncology, Winship Cancer Institute, Emory University, 2365 Clifton Road, N.E. Building C, Atlanta, GA 30322, USA

Received 1 March 2011; Accepted 20 April 2011

Academic Editor: A. Takeshita

Copyright © 2011 Abeer N. AbouYabis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Vose, J. Armitage, and D. Weisenburger, “International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4124–4130, 2008. View at Google Scholar
  2. M. M. C. Cheung, J. K. C. Chan, W. H. Lau et al., “Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 70–77, 1998. View at Google Scholar · View at Scopus
  3. B. Coiffier, N. Brousse, M. Peuchmaur et al., “Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives),” Annals of Oncology, vol. 1, no. 1, pp. 45–50, 1990. View at Google Scholar
  4. C. Gisselbrecht, P. Gaulard, E. Lepage et al., “Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas,” Blood, vol. 92, no. 1, pp. 76–82, 1998. View at Google Scholar · View at Scopus
  5. K. J. Savage, “Prognosis and primary therapy in peripheral T-cell lymphomas,” Hematology, pp. 280–288, 2008. View at Google Scholar · View at Scopus
  6. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Google Scholar · View at Scopus
  7. N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” Journal of the National Cancer Institute, vol. 22, pp. 719–748, 1959. View at Google Scholar
  8. C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Egger, G. Davey Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” BMJ, vol. 315, no. 7109, pp. 629–634, 1997. View at Google Scholar
  10. S. Duval and R. Tweedie, “Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis,” Biometrics, vol. 56, no. 2, pp. 455–463, 2000. View at Google Scholar · View at Scopus
  11. R. Liang, D. Todd, T. K. Chan et al., “Intensive chemotherapy for peripheral T-cell lymphomas,” Hematological Oncology, vol. 10, no. 3-4, pp. 155–161, 1992. View at Publisher · View at Google Scholar
  12. W. Siegert, A. Agthe, H. Griesser et al., “Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen: a multicenter study,” Annals of Internal Medicine, vol. 117, no. 5, pp. 364–370, 1992. View at Google Scholar
  13. T. Karakas, L. Bergmann, H. J. Stutte et al., “Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas,” Leukemia and Lymphoma, vol. 24, no. 1-2, pp. 121–129, 1996. View at Google Scholar
  14. S. Daum, R. Ullrich, W. Heise et al., “Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on intestinal non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2740–2746, 2003. View at Publisher · View at Google Scholar · View at PubMed
  15. P. Reimer, T. Schertlin, T. Rüdiger et al., “Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study,” Hematology Journal, vol. 5, no. 4, pp. 304–311, 2004. View at Publisher · View at Google Scholar · View at PubMed
  16. S. Wöhrer, A. Chott, J. Drach et al., “Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma,” Annals of Oncology, vol. 15, no. 11, pp. 1680–1683, 2004. View at Publisher · View at Google Scholar · View at PubMed
  17. J. G. Kim, S. K. Sohn, Y. S. Chae et al., “CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas,” Cancer Chemotherapy and Pharmacology, vol. 58, no. 1, pp. 35–39, 2006. View at Publisher · View at Google Scholar · View at PubMed
  18. S. H. Lee, Y. C. Ahn, W. S. Kim, Y. H. Ko, K. Kim, and K. Park, “The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma,” Haematologica, vol. 91, no. 3, pp. 427–428, 2006. View at Google Scholar
  19. H. J. Sung, S. J. Kim, H. Y. Seo et al., “Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study,” British Journal of Haematology, vol. 134, no. 1, pp. 45–53, 2006. View at Publisher · View at Google Scholar · View at PubMed
  20. M. J. Bishton and A. P. Haynes, “Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma,” British Journal of Haematology, vol. 136, no. 1, pp. 111–113, 2007. View at Publisher · View at Google Scholar · View at PubMed
  21. Y. Takamatsu, J. Suzumiya, A. Utsunomiya et al., “THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study,” European Journal of Haematology, vol. 84, no. 5, pp. 391–397, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. Y. L. Kwong, A. C. L. Chan, R. Liang et al., “CD56+ NK lymphomas: clinicopathological features and prognosis,” British Journal of Haematology, vol. 97, no. 4, pp. 821–829, 1997. View at Google Scholar
  23. A. López-Guillermo, J. Cid, A. Salar et al., “Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification,” Annals of Oncology, vol. 9, no. 8, pp. 849–855, 1998. View at Publisher · View at Google Scholar
  24. P. Pautier, A. Devidas, A. Delmer et al., “Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature,” Leukemia and Lymphoma, vol. 32, no. 5-6, pp. 545–552, 1999. View at Google Scholar
  25. V. Ribrag, M. E. Hajj, F. Janot et al., “Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx,” Leukemia, vol. 15, no. 7, pp. 1123–1126, 2001. View at Publisher · View at Google Scholar
  26. M. M. C. Cheung, J. K. C. Chan, W. H. Lau, R. K. C. Ngan, and W. W. L. Foo, “Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 1, pp. 182–190, 2002. View at Publisher · View at Google Scholar
  27. K. Kim, W. S. Kim, C. W. Jung et al., “Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification,” European Journal of Cancer, vol. 38, no. 1, pp. 75–81, 2002. View at Google Scholar
  28. M. Reiser, A. Josting, M. Soltani et al., “T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors,” Leukemia and Lymphoma, vol. 43, no. 4, pp. 805–811, 2002. View at Publisher · View at Google Scholar · View at PubMed
  29. T. Rüdiger, D. D. Weisenburger, J. R. Anderson et al., “Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project,” Annals of Oncology, vol. 13, no. 1, pp. 140–149, 2002. View at Publisher · View at Google Scholar
  30. C. S. Chim, S. Y. Ma, W. Y. Au et al., “Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index,” Blood, vol. 103, no. 1, pp. 216–221, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. C. C. Li, H. F. Tien, J. L. Tang et al., “Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma,” Cancer, vol. 100, no. 2, pp. 366–375, 2004. View at Publisher · View at Google Scholar · View at PubMed
  32. K. J. Savage, M. Chhanabhai, R. D. Gascoyne, and J. M. Connors, “Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification,” Annals of Oncology, vol. 15, no. 10, pp. 1467–1475, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. J. Y. You, K. H. Chi, M. H. Yang et al., “Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan,” Annals of Oncology, vol. 15, no. 4, pp. 618–625, 2004. View at Publisher · View at Google Scholar
  34. M. P. Escalón, N. S. Liu, Y. Yang et al., “Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience,” Cancer, vol. 103, no. 10, pp. 2091–2098, 2005. View at Publisher · View at Google Scholar · View at PubMed
  35. K. Kim, E. K. Chie, C. W. Kim, I. H. Kim, and C. I. Park, “Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy,” Japanese Journal of Clinical Oncology, vol. 35, no. 1, pp. 1–5, 2005. View at Publisher · View at Google Scholar · View at PubMed
  36. R. Sonnen, W. P. Schmidt, H. K. Müller-Hermelink, and N. Schmitz, “The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas,” British Journal of Haematology, vol. 129, no. 3, pp. 366–372, 2005. View at Publisher · View at Google Scholar · View at PubMed
  37. Y. X. Li, B. Yao, J. Jin et al., “Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 181–189, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. B. Coiffier, C. Gisselbrecht, R. Herbrecht, H. Tilly, A. Bosly, and N. Brousse, “LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma,” Journal of Clinical Oncology, vol. 7, no. 8, pp. 1018–1026, 1989. View at Google Scholar
  39. H. Q. Huang, Y. L. Peng, X. B. Lin et al., “Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen,” Chinese Journal of Cancer, vol. 23, no. 11, pp. 1443–1447, 2004. View at Google Scholar
  40. H. Tilly, P. Gaulard, E. Lepage et al., “Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome,” Blood, vol. 90, no. 9, pp. 3727–3734, 1997. View at Google Scholar
  41. E. C. Halperin, D. E. Dosoretz, M. Goodman, and C. C. Wang, “Radiotherapy of polymorphic reticulosis,” British Journal of Radiology, vol. 55, no. 657, pp. 645–649, 1982. View at Google Scholar
  42. G. E. Kim, J. H. Cho, W. I. Yang et al., “Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 54–63, 2000. View at Google Scholar
  43. G. E. Kim, S. W. Lee, S. K. Chang et al., “Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck,” Radiotherapy and Oncology, vol. 61, no. 3, pp. 261–269, 2001. View at Publisher · View at Google Scholar
  44. P. Sobrevilla-Calvo, A. Meneses, P. Alfaro, J. P. Bares, J. Amador, and E. E. Reynoso, “Radiotherapy compared to chemotherapy as initial treatment of angiocentric centrofacial lymphoma (polymorphic reticulosis),” Acta Oncologica, vol. 32, no. 1, pp. 69–72, 1993. View at Google Scholar
  45. M. Pfreundschuh, L. Trümper, M. Kloess et al., “Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL,” Blood, vol. 104, no. 3, pp. 634–641, 2004. View at Publisher · View at Google Scholar · View at PubMed
  46. M. Pfreundschuh, L. Trümper, M. Kloess et al., “Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL,” Blood, vol. 104, no. 3, pp. 626–633, 2004. View at Publisher · View at Google Scholar · View at PubMed
  47. W. S. Kim, S. Y. Song, Y. C. Ahn et al., “CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?” Annals of Oncology, vol. 12, no. 3, pp. 349–352, 2001. View at Publisher · View at Google Scholar
  48. R. I. Fisher, E. R. Gaynor, S. Dahlberg et al., “Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma,” The New England Journal of Medicine, vol. 328, no. 14, pp. 1002–1006, 1993. View at Publisher · View at Google Scholar · View at PubMed
  49. R. Gressin, M. Peoch, E. Deconinck et al., “The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T cell lymphoma. Final results of the “LTP95” protocol of the GOELAMS,” ASH Annual Meeting Abstracts, vol. 108, no. 11, p. 2464, 2006. View at Google Scholar
  50. H. Tilly, E. Lepage, B. Coiffier et al., “Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma,” Blood, vol. 102, no. 13, pp. 4284–4289, 2003. View at Publisher · View at Google Scholar · View at PubMed
  51. Y. L. Kwong, “Natural killer-cell malignancies: diagnosis and treatment,” Leukemia, vol. 19, no. 12, pp. 2186–2194, 2005. View at Publisher · View at Google Scholar · View at PubMed
  52. D. D. Weisenburger, J. R. Anderson, J. Diebold et al., “Systemic anaplastic large-cell lymphoma: results from the non-hodgkin's lymphoma classification project,” American Journal of Hematology, vol. 67, no. 3, pp. 172–178, 2001. View at Publisher · View at Google Scholar · View at PubMed
  53. J. P. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, 2009, Version 5.0.2, http://www.cochrane-handbook.org/.
  54. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Google Scholar
  55. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar
  56. B. Coiffier, E. Lepage, J. Brière et al., “CHOP chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at PubMed
  57. M. Wolf, J. P. Matthews, J. Stone, I. A. Cooper, T. I. Robertson, and R. M. Fox, “Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma,” Annals of Oncology, vol. 8, no. 1, pp. S71–S75, 1997. View at Google Scholar
  58. A. E. Hallack Neto, J. Pereira, B. Beitler et al., “Results of CHOP chemotherapy for diffuse large B-cell lymphoma,” Brazilian Journal of Medical and Biological Research, vol. 39, no. 10, pp. 1315–1322, 2006. View at Publisher · View at Google Scholar
  59. M. Jerkeman, H. Anderson, E. Cavallin-Ståhl et al., “CHOP versus MACOP-B in aggressive lymphoma—a nordic lymphoma group randomised trial,” Annals of Oncology, vol. 10, no. 9, pp. 1079–1086, 1999. View at Publisher · View at Google Scholar
  60. P. Feugier, A. Van Hoof, C. Sebban et al., “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d'etude des lymphomes de l'adulte,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4117–4126, 2005. View at Publisher · View at Google Scholar · View at PubMed
  61. F. Yun, “Pharmacodynamics and pharmacokinetics study of pegylated liposomal doxorubicin combined with cyclophosphamide, vincristine, and prednisolone in patients with peripheral T-cell lymphomas,” Journal of Clinical Oncology, vol. 28, no. 7s, supplement, abstract e18548, 2010. View at Google Scholar
  62. M. A. Thompson, B. Pro, A. Sarris et al., “Results of a phase II study of 506U78 (Nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma,” Blood, vol. 106, no. 11, p. 2681, 2005. View at Google Scholar
  63. R. Kurzrock, S. Pilat, and M. Duvic, “Pentostatin therapy of T-cell lymphomas with cutaneous manifestations,” Journal of Clinical Oncology, vol. 17, no. 10, pp. 3117–3121, 1999. View at Google Scholar
  64. A. M. Tsimberidou, F. Giles, M. Duvic, L. Fayad, and R. Kurzrock, “Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M. D. Anderson Cancer Center Series,” Cancer, vol. 100, no. 2, pp. 342–349, 2004. View at Publisher · View at Google Scholar · View at PubMed
  65. C. O. Rodriguez, C. M. Stellrecht, and V. Gandhi, “Mechanisms for T-cell selective cytotoxicity of arabinosylguanine,” Blood, vol. 102, no. 5, pp. 1842–1848, 2003. View at Publisher · View at Google Scholar · View at PubMed
  66. A. Goy, A. Bleyer, F. Hagemeister et al., “Phase II study of compound GW506U78 (AraG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy,” ASH Annual Meeting Abstracts, vol. 102, no. 11, Abstract #2359, 2003. View at Google Scholar
  67. S. L. Berg, S. M. Blaney, M. Bernstein et al., “Activity of compound 506U78 in patients with refractory T-cell malignancies: a POG/CCG intergroup phase 2 study,” ASH Annual Meeting Abstracts, vol. 102, no. 11, Abstract #792, 2003. View at Google Scholar
  68. H. T. Arkenau, G. Chong, D. Cunningham et al., “Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: The Royal Marsden Hospital experience,” Haematologica, vol. 92, no. 2, pp. 271–272, 2007. View at Publisher · View at Google Scholar
  69. M. Nickelsen, M. Ziepert, S. Zeynalova et al., “High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL),” Annals of Oncology, vol. 20, no. 12, pp. 1977–1984, 2009. View at Publisher · View at Google Scholar · View at PubMed
  70. N. Schmitz, L. Trumper, M. Ziepert et al., “Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group,” Blood, vol. 116, no. 18, pp. 3418–3425, 2010. View at Google Scholar
  71. Samsung Medical Center, “Bortezomib and CHOP in patients with advanced stage aggressive T cell or natural killer (NK)/T cell lymphomas,” 2009, http://clinicaltrials.gov/show/NCT00374699.
  72. P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu, “Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients,” Blood, vol. 96, no. 12, pp. 3712–3718, 2000. View at Google Scholar
  73. H. D. Foss, I. Araujo, G. Demel, H. Klotzbach, M. Hummel, and H. Stein, “Expression of vascular endothelial growth factor in lymphomas and Castleman's disease,” Journal of Pathology, vol. 183, no. 1, pp. 44–50, 1997. View at Publisher · View at Google Scholar
  74. M. Pfreundschuh, L. Trümper, A. Österborg et al., “CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group,” Lancet Oncology, vol. 7, no. 5, pp. 379–391, 2006. View at Publisher · View at Google Scholar · View at PubMed
  75. F. M. Foss, N. N. Sjak-Shie, A. Goy, R. Advani, and E. D. Jacobsen, “Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial,” Journal of Clinical Oncology, vol. 28, no. 7s, supplement, abstract 8045, 2010. View at Google Scholar
  76. A. Gallamini, F. Zaja, C. Patti et al., “Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial,” Blood, vol. 110, no. 7, pp. 2316–2323, 2007. View at Publisher · View at Google Scholar · View at PubMed
  77. J. S. Kim, S.-J. Kim, H. W. Lee et al., “A pilot study of alemtuzumab plus combination chemotherapy for newly diagnosed patients with peripheral T-cell lymphomas,” ASH Annual Meeting Abstracts, vol. 108, no. 11, p. 4717, 2006. View at Google Scholar
  78. A. Gallamini, F. Zaja, L. Gargantini et al., “CHOP chemotherapy plus campath-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL),” ASH Annual Meeting Abstracts, vol. 106, no. 11, p. 3345, 2005. View at Google Scholar
  79. T. Intragumtornchai, U. Bunworasate, T. N. Nakorn, and P. Rojnuckarin, “Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma,” ASH Annual Meeting Abstracts, vol. 108, no. 11, p. 4740, 2006. View at Google Scholar
  80. E. Weidmann, G. Hess, K. U. Chow et al., “A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas,” Leukemia and Lymphoma, vol. 51, no. 3, pp. 447–455, 2010. View at Publisher · View at Google Scholar · View at PubMed
  81. B. S. Kim, T. Y. Kim, C. W. Kim et al., “Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy: result of chemotherapy in NK/T-cell lymphoma,” Acta Oncologica, vol. 42, no. 7, pp. 779–783, 2003. View at Publisher · View at Google Scholar
  82. P. Reimer, T. Rüdiger, E. Geissinger et al., “Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: results of a prospective multicenter study,” Journal of Clinical Oncology, vol. 27, no. 1, pp. 106–113, 2009. View at Publisher · View at Google Scholar · View at PubMed
  83. J. Rodríguez, M. D. Caballero, A. Gutiérrez et al., “High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience,” Annals of Oncology, vol. 14, no. 12, pp. 1768–1775, 2003. View at Publisher · View at Google Scholar
  84. A. K. Blystad, G. Enblad, S. Kvaløy et al., “High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas,” Bone Marrow Transplantation, vol. 27, no. 7, pp. 711–716, 2001. View at Publisher · View at Google Scholar · View at PubMed
  85. A. P. Nademanee, J. M. Zain, J. Palmer et al., “The impact of disease status on the outcome of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) for peripheral T-cell lymphoma (PTCL),” ASH Annual Meeting Abstracts, vol. 108, no. 11, p. 3060, 2006. View at Google Scholar
  86. C. Haioun, E. Lepage, C. Gisselbrecht et al., “Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'etude des lymphomes de l'adulte study,” Journal of Clinical Oncology, vol. 18, no. 16, pp. 3025–3030, 2000. View at Google Scholar
  87. N. Mounier, D. Simon, C. Haioun, P. Gaulard, C. Gisselbrecht, and I. Khouri, “Impact of high-dose chemotherapy on peripheral T-cell lymphomas,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1426–1427, 2002. View at Google Scholar
  88. N. Mounier, C. Gisselbrecht, J. Brière et al., “All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA),” Annals of Oncology, vol. 15, no. 12, pp. 1790–1797, 2004. View at Publisher · View at Google Scholar · View at PubMed
  89. S. Mercadal, A. Lopez-Guillermo, J. Briones et al., “Is there a role for autologous stem-cell transplantation (ASCT) in peripheral T-cell lymphoma (PTCL)? Final results of a prospective phase II study from the GELCAB,” ASH Annual Meeting Abstracts, vol. 108, no. 11, p. 3070, 2006. View at Google Scholar
  90. F. d'Amore, T. Relander, G. Lauritzsen et al., “Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL)—a phase II study of the nordic lymphoma group (NLG),” ASH Annual Meeting Abstracts, vol. 108, no. 11, p. 401, 2006. View at Google Scholar
  91. O. O'Connor, B. Pro, L. Pinter-Brown et al., “PROPEL: results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL),” Journal of Clinical Oncology, vol. 27, no. 15S, p. 8561, 2009. View at Google Scholar
  92. K. Yim, I. Chau, A. Horwich et al., “Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma,” Journal of Clinical Oncology, vol. 28, no. 7s, supplement, abstract 8052, 2010. View at Google Scholar
  93. L. E. Budde, M. M. Zhang, A. R. Shustov et al., “A phase I study of vorinostat (V) in combination with rituximab (R), Ifosphamide, carboplatin, and etoposide (ICE) for patients with relapsed or refractory lymphoid malignancies or untreated T- or mantle cell lymphoma,” ASH Annual Meeting Abstracts, vol. 114, no. 22, p. 3696, 2009. View at Google Scholar
  94. R. Piekarz, J. Wright, R. Frye et al., “Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL),” ASH Annual Meeting Abstracts, vol. 114, no. 22, p. 1657, 2009. View at Google Scholar